Compare D R Horton Inc (DHI) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Enveric Biosciences Inc — how do they compare? D R Horton Inc trades at $135.82 (market cap $37.99B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.80M). The key difference: D R Horton Inc is far larger — about 5586.8× Enveric Biosciences Inc's market cap, and D R Horton Inc pays a 1.33% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Enveric Biosciences Inc for 14 Days on average.
| DHI | ENVB | |
|---|---|---|
Market Cap | $37.99B | $6.80M |
Volume | 2,974,460 | 64,867 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $10.80 |
52-Week Low | $132.53 | $1.27 |
Typical Hold Time | 46 Days | 14 Days |
Enterprise Value | $43.09B | -$1.49M |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) is trading at $133.28, down 2.54% with bearish technical signals. The stock shows attractive valuation metrics with P/E of 12.71 and P/S of 1.16, while maintaining solid profitability with 9.15% net margin. Recent earnings have consistently beaten expectations, though revenue declined to $34.25B in 2025. Technical indicators show oversold conditions with RSI at 26.75, while analyst consensus remains positive with $156.57 price target.
DHI presents a value opportunity with strong fundamentals but faces near-term headwinds from rising mortgage rates and housing market weakness. The 47% upside to consensus target offers potential reward, though investors must weigh housing sector volatility against the company's consistent execution and shareholder returns including dividends and buybacks.
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
